RxDoctor Payments Data

Tracy McIntosh

Family · Sumter, SCNPI 1700456837

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 46 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$142
  • Bayer$133
  • AstraZeneca$127
  • AbbVie$118
  • Lilly USA, LLC$115
  • Idorsia Pharmaceuticals US Inc$112
  • plus $367 from 11 others

What the payments were for

  • Food & beverage$1,114100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,114 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$73,821
Medicare patients
219
Services billed
3,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$55,194
TrulicityDulaglutide14$17,067
LinzessLinaclotide14$11,722
OzempicSemaglutide12$11,639
JanuviaSitagliptin Phosphate11$5,939
NexiumEsomeprazole Magnesium11$2,708
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,023
Albuterol Sulfate HfaAlbuterol Sulfate59$1,811
Atorvastatin Calcium121$1,469
Levothyroxine Sodium46$768
Gabapentin53$629
Rosuvastatin Calcium50$355
Losartan Potassium51$354
Omeprazole24$319
Diclofenac Sodium20$298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$28$55,19460 claims
Lilly USA, LLCTrulicity$115$17,06714 claims
AbbVieLinzess$118$11,72214 claims
Novo NordiskOzempic$142$11,63912 claims
AstraZenecaNexium$127$2,70811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,248 family providers in South Carolina.

Other family in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →